Inclusion Criteria:

1. Patients undergoing a radical course of RT for high-risk disease (defined according
to the National Comprehensive Cancer Network Practice Guidelines in Oncology v.1 as
one or more of the NCCN high risk criteria > or equal to T3, > or equal to Gleason 8,
PSA > 20ng/ml)

2. Only patients requiring neo-adjuvant / adjuvant hormonal therapy will be included in
this study

3. Absence of distant metastases as demonstrated by history and physical examination,
FBC, screening profile including liver function tests, PSA and bone scan

4. All patients must have an MRI/CT of the prostate and pelvis to investigate the nodal
status and precise T-stage. This MRI/CT scan must be performed prior to commencement
of hormonal therapy. Suspicious nodes need to be histologically proven to be benign
before the patient can be included in the study). M0 on staging.

5. No previous surgery for urinary conditions except TURP or TRUS

6. KPS > or equal to 60

7. Age >18 years

8. Provision of written informed consent in line with ICH-GCP guidelines

Exclusion Criteria:

1. Previous RT to the pelvic region

2. The patient has nodal involvement or it is decided to electively treat pelvic lymph
nodes

3. The patient has had a bilateral orchidectomy

4. The patient has previously received a full course of hormonal treatment for his
prostate cancer

5. The patient has or has had other malignancies within the last 5 years (non-melanoma
skin cancer is permitted)

6. Evidence of any other significant clinical disorder or laboratory finding that makes
it undesirable for the patient to participate in the trial or if it is felt by the
research/ medical team that the patient may not be able to comply with the protocol

7. Patients who have had a prostatectomy

8. The presence of hip prostheses